Epirubicin/vinorelbine as first line therapy in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 49, Issue 2, 1998, Pages 129-134

  Baldini, Editta ^a   Tibaldi, Carmelo ^a   Chiavacci, Franco ^b   Di Lieto, Marco ^b   Fioretto, Luisa ^c   Giallombardo, Annalia ^c   Taviani, Roberto ^d   Ghezzi, Paolo ^e   Bolognini, Anna ^e   Conte, Pierfranco ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b Div di Radioterapia Osp di Pistoia   (Italy)

^c Serv Med Oncologica Osp SM A   (Italy)

^d Div di Chirurgia Ospedale di Empoli   (Italy)

^e Div di Oncol Medica Osp di Arezzo   (Italy)

Author keywords

Epirubicin vinorelbine combination chemotherapy; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ALKALOID; EPIRUBICIN; NAVELBINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUTROPENIA; PARALYTIC ILEUS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 14444278732     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006059211817     Document Type: Article

References (22)

1. Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Disease, 2nd ed. J.B, Lippincott, Philadelphia, 1991, pp 604-665
2. Mourisden HT: Systemic therapy of melastatic breast can cer. Drugs 44: 17-28, 1992
3. Gianni L, Munzone E, Capri G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995
4. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7: 687-693, 1996
5. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours; a regimen with high activity and low eardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510-2517, 1997
6. Ayash LJ, Elias A, Wheeler C: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12: 37-44, 1994
7. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13: 2483-2489, 1995
8. Peters WP, Jones RB, Vredenbourg J et al.: A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastalic breast cancer achieving complete remission after intensive doxorubicinbased induction therapy (AFM). Proc Am Soc Oncol (abstr) 149: 121, 1996
9. Cvitkovic E, Izzo J: The current and future place of vinorelbine in cancer therapy. Drugs 44 (4): 36-45, 1992
10. Mathe G, Reizensten P: Phase I pharmacology study of a new vinca-alkaloid: Navelbine. Cancer Lett 27: 285-293, 1985
11. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M: Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252, 1993
12. Garcia-Conde J, Lluch A, Martin M: Phase II study of Navelbine in advanced breast cancer. Ann Oncol 5: 854-857, 1994
13. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T, Merle S: Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12: 1764-1770, 1994
14. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 6: 679-688, 1988
15. Italian Multicenter Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer. J Clin Oncol 6: 976-982, 1988
16. Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mourisden HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14: 1146-1155, 1996
17. Simon R: Optimal two stage design for phase II clinial trials. Controlled Clin Trials 10: 1-10, 1989
18. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958
19. Greenberg PAC, Hortobagyi G, Smith TL: Long term follow-up of patients with complete remission following combination chemotherapy for metastalic breast cancer. J Clin Oncol 14: 2197-2205, 1996
20. Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epirubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 14: 764-773, 1996
21. Blomqvist C, Hietanen P, Teerenhovi L, Rissanen P: Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer 31: 2406-2408, 1995
22. Gridelli C, De Placido S, Pepe R: Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small-cell lung cancer. Eur J Cancer 12: 1729-1731, 1993